These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results? Toyoda H; Kumada T; Tada T Hepatology; 2014 Aug; 60(2):762-3. PubMed ID: 24519154 [No Abstract] [Full Text] [Related]
4. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis]. Nishiguchi S; Kubo S; Shiomi S Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868 [No Abstract] [Full Text] [Related]
5. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522 [TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ]. Yoshida H; Tateishi R; Omata M Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852 [No Abstract] [Full Text] [Related]
7. Development of hepatocellular carcinoma after sustained response to interferon therapy: how long should sustained responders with risk factors be followed? Kasahara A J Gastroenterol; 2005 Feb; 40(2):220-2. PubMed ID: 15770412 [No Abstract] [Full Text] [Related]
8. [Chronic hepatitis C in hemodialysis patients]. Tanaka H; Ueda H; Ichinose M; Miyano M Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):645-8. PubMed ID: 15359877 [No Abstract] [Full Text] [Related]
9. [Histological findings in the liver in patients with chronic hepatitis C]. Takase K; Shiraki K Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):434-8. PubMed ID: 15359838 [No Abstract] [Full Text] [Related]
10. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Kowdley KV Gastroenterology; 1999 Sep; 117(3):738-9. PubMed ID: 10464154 [No Abstract] [Full Text] [Related]
11. Symposium on clinical aspects in hepatitis virus infection. 4. Topics of type C chronic liver disease. Hayashi N Intern Med; 2001 Feb; 40(2):180-1. PubMed ID: 11300162 [No Abstract] [Full Text] [Related]
12. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762 [TBL] [Abstract][Full Text] [Related]
13. Interferon therapy reduces the risk for hepatocellular carcinoma. Brown JL Gut; 2000 Nov; 47(5):610-1. PubMed ID: 11034573 [No Abstract] [Full Text] [Related]
14. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or a clue to the flaws? Farrell GC J Gastroenterol Hepatol; 1999 Sep; 14(9):833-7. PubMed ID: 10535462 [No Abstract] [Full Text] [Related]
15. 'Yes, now you are free from chronic HCV infection, but . . .'. Toyoda H; Kumada T J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):9-10. PubMed ID: 16706803 [No Abstract] [Full Text] [Related]
16. Current status of antiviral therapy for chronic hepatitis C. Lemon SM Adv Exp Med Biol; 1999; 458():29-37. PubMed ID: 10549377 [No Abstract] [Full Text] [Related]
18. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it? Blanco JR; Rivero-Juárez A Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837 [No Abstract] [Full Text] [Related]